Convenzione HT: first round of consultations underway
The Convenzione signed on 30 December 2020 between the Ministry of Economy and Finance, the Ministry of Health, the Ministry of University and Research and the Human Technopole Foundation regulates the creation of National Facilities (NFs) at HT, to be made available to the Italian scientific community to conduct high quality research in their respective fields, independent of institutional affiliation.
The Convenzione foresees that such National Facilities will be identified through a two-stage consultation process: the first phase addressed to selected stakeholders representing the life science research system, the second to the entire scientific community.
The first phase kicked off on 23 July as a questionnaire was sent to a list of representatives of Universities, research hospitals, research centres, research funding organisations and the life science industry identified by the Convenzione’s Technical Committee. The Committee is composed of two Director Generals of the Ministry of Health and the Ministry of University and Research, one Italian delegate of ESFRI, the Chair of Human Technopole’s Scientific Advisory Board and the Director of Human Technopole.
The questionnaire, largely based on the form used by ESFRI to collect proposals for research infrastructures to be included in the European roadmap, will allow to identify the national life science community’s perceived priorities with regard to research infrastructures and to collect adequately motivated proposals for possible National Facilities to be implemented at Human Technopole.
The indications resulting from this first phase will then be made available for feedback to the Italian scientific community during a second round of consultations to take place in the autumn of 2021.
Documents:
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.